New drug SP-624 targets brain waves in depression study
NCT ID NCT06570369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested whether the experimental drug SP-624 affects brain electrical activity in 26 people — some healthy, some with major depression. Participants took SP-624 or a placebo daily for two weeks. Researchers used EEG and AI to look for changes in brain networks, and also checked memory and learning in those with depression. The main goal was to see if SP-624 has any measurable effect on the brain, not yet to treat the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SP-624
What this could lead to
If this early study shows SP-624 changes brain activity in a helpful way, it could point toward a new treatment for depression.
What could go wrong
This is a very small, early Phase 1 trial focused on measuring brain signals, not treating depression. It may show no meaningful effect, and results may not lead to a real treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alivation Research
Lincoln, Nebraska, 68526, United States
-
CenExel CNS
Garden Grove, California, 92845, United States